睿智医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：创新药、抗癌治 癌、AI医药、CRO概念、阿尔茨海默等。 11月14日，睿智医药盘中上涨2.40%，截至10:48，报11.52元/股，成交1.04亿元，换手率1.94%，总市值 57.37亿元。 资金流向方面，主力资金净流入182.84万元，特大单买入378.07万元，占比3.62%，卖出343.06万元，占 比3.29%；大单买入2199.10万元，占比21.06%，卖出2051.27万元，占比19.65%。 睿智医药今年以来股价涨79.44%，近5个交易日涨6.47%，近20日涨2.58%，近60日跌10.70%。 今年以来睿智医药已经2次登上龙虎榜，最近一次登上龙虎榜为7月29日，当日龙虎榜净买入1.65亿元； 买入总计2.56亿元 ，占总成交额比16.71%；卖出总计9095.17万元 ，占总成交额比5.93%。 资料显示，睿智医药科技股份有限公司位于广东省广州市越秀区东风中路268号交易广场28楼，成立日 期2000年1月26日，上市日期2010年12月22日，公司主营业务涉及医药研发与生产外包服务、微生态营 养、微生态医 ...

Core Viewpoint - The company, Ruizhi Pharmaceutical, has shown a mixed performance in terms of financing activities and stockholder metrics, with notable growth in revenue and net profit for the first half of 2025 [1][2]. Financing Activities - On September 24, 2023, Ruizhi Pharmaceutical's stock price increased by 0.33%, with a trading volume of 178 million yuan. The financing buy-in amount was 14.89 million yuan, while the financing repayment was 17.60 million yuan, resulting in a net financing outflow of 2.70 million yuan [1]. - As of September 24, 2023, the total financing and securities lending balance for Ruizhi Pharmaceutical was 234 million yuan, which accounts for 3.91% of its market capitalization. The financing balance is above the 80th percentile of the past year, indicating a high level [1]. - In terms of securities lending, there were no shares sold or repaid on September 24, 2023, with a remaining securities lending balance of 11.39 million yuan, which is above the 60th percentile of the past year, also indicating a high level [1]. Shareholder Metrics - As of September 20, 2023, the number of shareholders for Ruizhi Pharmaceutical was 44,700, a decrease of 5.99% from the previous period. The average number of circulating shares per shareholder increased by 6.37% to 10,626 shares [2]. - The company has cumulatively distributed 180 million yuan in dividends since its A-share listing, with no dividends distributed in the past three years [3]. Financial Performance - For the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 534 million yuan, representing a year-on-year growth of 14.75%. The net profit attributable to the parent company was 25.38 million yuan, showing a significant year-on-year increase of 140.35% [2].